The CYP11A1 gene encodes P450scc (cholesterol side-chain cleavage enzyme), which catalyzes the first step for the synthesis of steroids. Expression of CYP11A1 is controlled by transcription factor SF-1 (steroidogenic factor 1). Two functional SF-1-binding sites, P and U, located at ؊40 and ؊1,600 
INTRODUCTION
Steroids are circulating hormones secreted from endocrine glands in minute amounts. The first and ratelimiting step for the synthesis of steroids is catalyzed by cholesterol side-chain cleavage enzyme (cytochrome P450scc), which is encoded by CYP11A1. The expression of the CYP11A1 gene is tightly regulated for proper steroid secretion (1, 2) . CYP11A1 is mainly expressed in the adrenal and gonads, as well as placenta during pregnancy (3) . In addition to these major endocrine glands, Cyp11a1 is also expressed in the brain, producing neurosteroids (4) (5) (6) . With the exception of brain and placenta, which appear to have different control mechanisms (3, 7) , the adrenals and gonads share similar machinery for the regulation of CYP11A1 gene expression (8) .
The expression of CYP11A1 in the adrenal and gonads is stimulated by pituitary hormone (2) . ACTH secreted by pituitary stimulates expression of CYP11A1 in the adrenal. Similarly, gonadotropins secreted from the pituitary stimulate CYP11A1 gene expression in gonads. These pituitary hormones bind to the G protein-coupled receptors located at the cell surface of the adrenal or gonads and trigger the increase of intracellular cAMP. cAMP is the intracellular messenger that transmits signals to the nucleus to increase transcription of the CYP11A1 gene (9, 10) . In addition to this hormonal regulation, Cyp11a1 expression in the adrenal and gonads is also regulated developmentally, starting at embryonic day 11, and persists throughout life (11) .
Mechanisms controlling CYP11A1 gene expression in the adrenal and gonads have been dissected. Two sequences located at the proximal (Ϫ40) and upstream (Ϫ1,600) regions of the human CYP11A1 gene have been shown to bind transcription factor SF-1 (steroidogenic factor 1), which triggers cAMP-dependent gene expression in cell culture studies (12) (13) (14) . SF-1 [also termed Ad4BP or NR5A1 (15, 16) ] is a transcriptional activator expressed in the adrenal, gonads, pituitary gonadotropes, and ventromedial nucleus of the hypothalamus (11, 17, 18) . SF-1 controls expression of not only steroidogenic genes (19) , but also genes of secreted signaling molecules such as gonadotropin (20) , Mü llerian inhibiting substance (21, 22) , and oxytocin (23) .
Despite a great deal of in vitro studies, final proofs showing that SF-1 can activate Cyp11a1 gene expression in vivo is lacking. Generation of SF-1 null mutation in mice results in the loss of adrenals and gonads (24) , thus precluding studies of Cyp11a1 gene expression due to the lack of tissues in which Cyp11a1 is expressed. To alleviate this problem, we have devised a transgenic mouse study employing wild-type and mutant CYP11A1 promoters connected to a LacZ reporter gene to address the function of SF-1-binding sites in vivo.
Furthermore, the functions of the two SF-1-binding sites located at the proximal and upstream regions of the CYP11A1 promoter have not been dissected carefully. Earlier studies showed that both sites are important for cAMP-dependent transcription in vitro (12) (13) (14) . The functional roles of these two sites in vivo have not been addressed. We mutagenized these two sites individually and were able to dissect the functions of these cis-acting elements into basal transcriptional activation and cAMP response in our transgenic mouse studies. The proximal SF-1-binding site was essential for transcription. The upstream site, while contributing to some basal transcription, appeared to function in the control of hormonal response.
RESULTS

Function of the Two SF-1-Binding Sites in Vitro
About 2 kb of the human CYP11A1 promoter have been studied extensively. Of the six potential SF-1-binding sites (15) , only two sites, located at Ϫ40 and Ϫ1,600 (Fig. 1) , were functional in our earlier experiments (14) . To further explore the functions of these two sites, we mutagenized both the upstream (U) and proximal (P) SF-1-binding sites. Electrophoretic mobility shift assay shows that both U and P form a complex with proteins from mouse adrenocortical cell Y1 (Fig. 2) . This complex was competed away by unlabeled wild-type P or U sequence, but not by a nonspecific competitor (N.S.), nor by the mutated mtP or mtU sequence. These data indicate that the mutated mtU or mtP sequence can no longer bind to SF-1.
To test the function of both SF-1-binding sites, we transfected the wild-type and mutated promoters into Y1 cells and scored reporter ␤-galactosidase (␤-gal) gene activity (Fig. 3) . We tested wild-type promoters of 2.3-and 1.7-kb lengths, to determine whether the adrenal enhancer (AdE) sequence that we previously identified at the 1.9-kb region functions in this assay (25) . There is no significant difference in transcription driven by either 2.3-or 1.7-kb wild-type promoters. In addition, the mutated mtU promoter has similar activity to the 2.3-kb wild-type promoter. The mtP and mt2X (double mutation) promoters, however, are inactive, showing ␤-gal values similar to that of the pro- The 2.3k and 1.7k plasmids contain 2,300-bp and 1,700-bp 5Ј-sequence of the CYP11A1 gene linked to a LacZ reporter gene, respectively. Restriction sites for the ApaI and HindIII are indicated. AdE represents an adrenal-specific enhancer that is absent in the 1.7k plasmid. The site that binds Sp1 family members is represented as an oval shape. The cAMP-responsive region located between Ϫ1,500 and Ϫ1,620 is indicated as cAMP. Two binding sites for SF-1 located at the proximal (Ϫ40) and upstream (Ϫ1,600) regions are shown together with their sequences. Mutations (sequences shown in lowercase) were introduced into the proximal, upstream, and both SF-1-binding sites, to form mtP, mtU, and mt2X, respectively. The lines in front of the LacZ box indicate the transcription initiation sites of the reporter gene.
moterless LacZ plasmid. This result demonstrates that the proximal and upstream SF-1-binding sites do not have the same function in gene activation.
Function of the Two SF-1-Binding Sites in Transgenic Mice
To further investigate the control of the CYP11A1 gene expression in vivo, we generated transgenic mouse lines containing the LacZ gene under the control of different lengths of wild-type or mutated promoter fragments. Expression of the transgene varies a great deal among different transgenic mouse lines, depending on the promoter strength, site of integration, and number of transgene copies, as studied in detail previously (26) . Even with such variability, we found that the 2.3-and 1.7-kb fragments both direct reporter gene expression in the adrenal, as shown by the presence of many transgenic lines (represented by filled circles) that express significant levels of ␤-gal activities (Fig. 4) . LacZ gene expression driven by the 1.7-kb promoter was also detected in the fetal adrenal primordia, starting at embryonic day 11.5 (data not shown), similar to the developmental regulation observed for the 4.4-kb promoter (26) .
Transgenic lines from both mtP and mtU constructs have markedly reduced reporter gene expression in the adrenal compared with those from the wild-type promoters (Fig. 4) . The double mutant, mt2X, lost activity completely. None of the 16 transgenic lines generated from this construct has any ␤-gal activity above background. These results show that mutations of both P and U sites are deleterious in vivo, while the P site appears to have a more severe effect when mutated.
Some transgenic mice harboring the mtU promoter retain a low level of ␤-gal activity (Fig. 4) . Line U4 is the only one among all mtU lines that still has appreciable amounts of ␤-gal activity in the adrenal. We examined whether expression of the reporter gene in this line is tissue specific. Figure 5 shows that ␤-gal activities from the U4 line can be detected in male and female adrenals, ovary, testis, and brain. Transgene expressions are absent in heart, kidney, lung, liver, and spleen. This expression pattern is similar to that from wild-type 1.7k mice (Fig. 5 and results for three other lines) and the 2.3k mice (26) . Generally, the expression of the reporter gene from the mtU construct remains tissue specific. This result is reasonable considering The gels show the electrophoretic mobility shift assay using the proximal (P) or the upstream (U) SF-1-binding site as the probe for interaction with proteins in the nuclear extract from adrenocortical Y1 cells. Competitors are shown on top of each lane; Ϫ, no competitor used; N.S., a nonspecific competitor oligo. that sequences in the basal promoter including the P site are still preserved.
We also tested hormonal regulation of the mutated promoter by injecting hormones into transgenic mice. Previously we have shown that reporter gene expressions directed by the 2.3k and 4.4k promoters are stimulated by ACTH or human CG (hCG) injection in vivo (26, 31a) . Figure 6 shows that ␤-gal expression from the adrenal of the mouse line containing the 1.7k construct is stimulated by ACTH, whereas that from the mtU line can not respond to ACTH. ␤-Gal activities from the mtP adrenals are extremely low both before and after ACTH stimulation. Similarly, in the testis, the 1.7k construct can be stimulated by hCG injection, but the mtU promoter cannot. These results show that mutation of the upstream SF-1-binding site abolishes hormonal response in both adrenal and testis.
DISCUSSION
We have studied the function of both proximal and upstream SF-1-binding sites in the human CYP11A1 promoter both in vitro and in vivo. The proximal SF-1-binding site is situated in the basal promoter region, with the TATA box on one side and a sequence that can bind to Sp-1 family members on the other. This core promoter region is essential for tissue-specific gene expression in vitro, as shown previously (14, 27) . Our present study demonstrates that mutation of the proximal SF-1-binding site results in almost complete loss of gene expression in transgenic mice. This proximal SF-1-binding site is therefore required for the core promoter function, both in vitro and in vivo.
The function of the upstream SF-1-binding site in basal gene expression, on the other hand, is less obvious. Mutation of this site does not have a significant effect in vitro (Fig. 3) . Using transgenic mice, we obtained a mouse line that still expresses the reporter gene at a reasonable level, although the overall expression levels in most mutant lines are low. It appears that a notable function of this upstream SF-1-binding site is in the response to hormonal stimulation. Mutation of this upstream site leads to loss of hormonal response.
The upstream SF-1-binding site is located in the cAMP-responsive region, which is a 100-bp fragment mediating hormonal stimulation of gene expression in vitro (13, 14, 28) . This region binds proteins in the cAMP response element binding protein (CREB)/AP1 families in addition to SF-1 (12, 29) . The involvement of SF-1 in cAMP response was equivocal, as SF-1 phosphorylation has not been correlated with cAMP response (30, 31) , but mutation of the AF-2 activation domain of SF-1 suppresses protein kinase A-dependent transactivation of gene expression (32) . The present result shows that the upstream SF-1-binding site U is indeed important for hormonal response in vivo. SF-1 is known to interact with proteins like WT1 (33) and c-Jun for enhanced transcription (34, 35) , and with DAX-1 for reduced transcription (33) . Therefore, SF-1 participates in cAMP response probably through its interaction with proteins that bind to the upstream cAMP-responsive sequence, rather than via its own phosphorylation by cAMP-dependent protein kinase A. 
Fig. 6. Hormonal Stimulation of Reporter Gene Expression in Transgenic Mice
A, Effect of ACTH on adrenal gene expression. Female transgenic mice from line C63 of construct 1.7k, line P62 of construct mtP, and line U4 of construct mtU were injected with ACTH or NaCl daily for 7 days. Adrenal homogenates of these mice were then assayed for ␤-galactosidase activities. B, Effect of hCG on testis gene expression. Male transgenic mice from line C43 of construct 1.7k and line U4 of construct mtU were injected with hCG or NaCl twice a day for 6 days. ␤-Galactosidase activities of the testis homogenate were then measured. The mean ␤-galactosidase activities per tissue isolated from three to seven mice are shown with error bars representing standard errors.
In addition to the loss of hormonal response, we also noticed a reduction of reporter gene expression in vivo upon mutation of the upstream SF-1-binding site. Most mtU transgenic lines (18 of 22) do not express the reporter gene. On the contrary, about half of the wild-type transgenic lines (5 of 11 for the 2.3k-and 9 of 14 for the 1.7k-constructs) express reporter gene well (Fig. 4) . This indicates that the upstream SF-1-binding site still has a role in gene expression. Most of the mtP lines do not express reporter gene, except one transgenic line that has a slightly higher than background level of reporter gene expression (Fig. 4) . These results show that, in vivo, the proximal SF-1-binding site has a major activation function. The upstream site also contributes to some extent.
Our data from transgenic mice do not completely agree with the transfection data, which failed to identify function of the upstream SF-1-binding site (Fig. 3) . There are also other reports showing that in vivo results do not agree with in vitro data (36) (37) (38) . The reason for the discrepancy could be the use of a tumor cell line that does not fully simulate the situation in vivo. Another possibility is the difference of transgene structure in transfection and transgenic mouse experiments. The transgenes are integrated into the chromosomes of transgenic mice, whereas in transient transfection experiments transgenes are assayed before integration into the chromosome. The absence of chromatin structure in the transiently transfected DNA might result in aberrant results. It is therefore essential to verify the results obtained from cell culture by in vivo experiments.
CYP11A1 gene expression in the adrenal and gonads is stimulated by peptide hormones such as ACTH and gonadotropins. These hormones stimulate CYP11A1 gene expression to maintain the differentiated state of the tissue (1). They cannot induce CYP11A1 gene expression, however, when the cells are not steroidogenic. It appears that basal gene expression is required for hormonal response. Without basal gene expression, as in the case of proximal SF-1-site mutant, hormones can no longer stimulate transcription. This proximal SF-1-binding site is a major regulator of basal gene expression. The contribution of the upstream SF-1-binding site to activate basal transcription, on the other hand, is less prominent, thus manifesting its other function for hormonal response. Therefore, the proximal site appears to control basal transcription, whereas the importance of the upstream site lies mainly in hormonal response. Although the upstream and proximal SF-1-binding sites of the human CYP11A1 promoter are similarly involved in transcriptional activation, their physiological roles may appear different.
A few reports have documented the function of SF-1 in vivo. One is the demonstration of the requirement of the SF-1-binding site for the activity of the LH ␤-subunit promoter (20) . The other is the use of a short, 180-bp Mü llerian inhibiting substance (Mis) promoter to show that the SF-1-binding site is essential for gene activation (39) . Both studies reach the simple conclusion that SF-1 is indispensable for transcription after studying two to six transgenic mouse lines. In a more refined approach, which examined the function of the mutated SF-1-binding site in the Mis promoter by the homologous recombination (knock-in) procedure, SF-1 appears to act as a quantitative regulator of Mis transcript levels (37) . A recent report also shows haploid insufficiency of mice with heterozygous SF-1 function (40) . Therefore, SF-1 does not act in an all-or-none fashion; instead, it regulates transcription in a quantitative manner. This is consistent with our data showing that there may be a strength difference between the upstream and the proximal SF-1-binding sites. The reason for our ability to distinguish the variation in SF-1 action is probably due to the relatively large number of transgenic mouse lines used in this study (10-30 lines) , which allowed detailed analyses.
MATERIALS AND METHODS
The proximal (P) and upstream (U) SF-1-binding sites from pSCC2300 (31a) were mutated separately using the Sculptor in vivo Mutagenesis System (Amersham Pharmacia Biotech, Uppsala, Sweden). Mutant oligos are mtP: AACTACCAGCT-CACGGTGATACCAGAAGCTG; and mtU: TGCCTCACTGAT-CATCGTGAGCCTGGAATG. The double mutant (mt2X) was constructed by replacing the HindIII to ApaI fragment of pmtP with that from pmtU.
The conditions for gel shift experiments were like those previously described (14) , except that 10 g of extract were used for each reaction. Sequences of the sense strand of the oligos used in gel shift are as follows: U, CTAGACAAGGT-CATCAT; P, TCGACTTCTGGTATGGCCTTGAGCTGGTAG; mtP, CAGCTTCTGGTATCACCGTGAGCTGGTAGTT; mtU, CATTCCAGGCTCACGGTGATCAGTGAGGCA; N.S., CTA-GATTCATGACTGATGAGGTAGTGGT.
Transfections were performed using either supercoiled or linearized plasmids. Cells were harvested 24 h after the addition of 1 mM 8-Br-cAMP, and ␤-galactosidase activity was measured by chemiluminescent detection as previously described (26, 35) . Injected DNA fragments consisted of the CYP11A1 promoter linked to LacZ and SV40 polyA. Unless otherwise specified, the length of the test promoter was 2.3 kb. Fifteen, 8, 22 , and 16 transgenic founders were obtained from the 1.7k, mtP, mtU, and mt2X constructs, respectively. The transgene copy numbers in the genome of transgenic mice determined by Southern blotting were mostly below 5, in a range of 1-30. All transgenic founders and their offspring were of the FVB strain. Genomic DNA was prepared from tails or placentas of embryos. Genotyping was performed by PCR amplification of LacZ with primers 5Ј-Gal (AGGCATTGGTCT-GGACACCAGCAA) and 3Ј-Gal (GATGAAACGCCGAGTTA-ACGCCAT), producing a 476-bp fragment.
Mice were housed under standard specific pathogen free laboratory conditions. Five to seven female transgenic mice were injected with ACTH as previously described (26) . Six male transgenic mice were injected with 10 IU hCG or saline (Sigma, St. Louis, MO) ip twice a day for 6 days. ␤-Galactosidase activities were measured from adrenal or testis tissue homogenates according to a method described previously (26) .
Experimental Animals
All studies concerning the use of mice were conducted in accord with the rules established by the Animal Committee at the Institute of Molecular Biology, Academia Sinica.
